Last updated on July 2019

Ovarian Autologous Platelet-Rich Plasma (PRP) Treatment in Premature Ovarian Failure.


Brief description of study

The specific prospective Randomnised Clinical Trial, attempts to investigate whether autologous Platelet Rich Plasma (PRP) injected into the ovaries of Premature Ovarian Failure (POF) patients, may lead to reactivation of the ovarian function.

Autologous PRP is obtained from the patients' own blood, collected from the peripheral veins, prior to the treatment. Following centrifugation, PRP presents with an increased platelet concentration. Due to its growth factors and cytokines contained within, PRP is shown to stimulate tissue proliferation and growth. Examples of such factors are the vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and others. PRP has been employed in several medical conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. It's efficacy in ovarian function has not been fully elucidated.

The aim of this study is to evaluate the effectiveness of ovarian PRP injection in order to reactivate ovarian function.

Clinical Study Identifier: NCT04031456

Find a site near you

Start Over

Genesis AC

Athens, Greece
  Connect »